Greenwich LifeSciences, Inc. (GLSI) Stock Price & Analysis
Greenwich LifeSciences, Inc. (GLSI) is trading at USD 20.08, up 7.35% today, as of November 18, 2026 at 17:13 UTC (US market open; quotes may be delayed), according to Nexqual market data.
GLSI last closed at USD 18.7; today's session has ranged USD 18.24–21.22 on volume of 420,435 shares. Market capitalization is $294.67M, with a 52-week range of USD 7.78–34.1 (NCM). Source: Nexqual, retrieved November 18, 2026 at 17:14 UTC.
What changed for GLSI since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Greenwich LifeSciences, Inc. (GLSI) stock went from USD 11.48 (close of the week of Aug 25, 2025, split-adjusted) to USD 20.08, a +74.9% price change; the S&P 500 (SPY) moved +14.7% over the same period.
Also available as compact Markdown for AI agents: nexqual.com/GLSI.md
Key facts (GLSI)
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $97K; 0 by opportunistic insiders, 3 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 57.5 (range 45–70).
- Total return with dividends: 1Y +143.6% vs S&P 500 +11.8%; 5Y -42.4% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: GLSI paid no cash dividend in the last five years.
- Short interest: 20.64% of float (as of 2026-10-30), 11.5 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GLSI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$4.6M | -$8.0M | -$9.3M | -$17.6M | -$19.4M | -$24.8M |
| Net income | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M | -$24.6M |
| EPS (diluted) | -$0.35 | -$0.61 | -$0.69 | -$1.34 | -$1.43 | — |
| Cash + short-term investments | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (GLSI)
Earnings yield -8.34%
Insider purchases (SEC Form 4, open-market, last ~7 months) (GLSI)
3 purchases, $97K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-28…2026-07-29 | Patel Snehal | CEO and CFO | 2,200 | $30K | 13.43 | Routine (bought in Apr each year 2023–2025; this trade is outside those months) |
| 2026-07-27 | Patel Snehal | CEO and CFO | 1,500 | $20K | 13.62 | Routine (bought in Apr each year 2023–2025; this trade is outside those months) |
| 2026-07-23…2026-07-24 | Patel Snehal | CEO and CFO | 3,600 | $47K | 13.06 | Routine (bought in Apr each year 2023–2025; this trade is outside those months) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (GLSI)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 57.5 (low 45, high 70).
Total return (dividends reinvested) (GLSI)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | +143.6% | -42.4% |
| S&P 500 (SPY) | +11.8% | +66.5% |
| Per year | +143.8% | -10.4% |
| Volatility (annualized) | 110.3% | 68.4% |
| Max drawdown | -61.9% (Jan 2026→Jul 2026) | -78.9% (Nov 2021→Jun 2022) |
Dividends (GLSI)
GLSI paid no cash dividend in the last five years.
Short interest (GLSI)
1,578,166 shares sold short, 20.64% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,580,950 shares (-0.2%). Days to cover: 11.5 (short shares ÷ average daily volume).
GLSI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.40 | −$0.33 | Miss −21.2% | — |
| — | Quarter ended Jun 30, 2026 | −$0.27 | −$0.33 | Beat +18.2% | — |
| — | Quarter ended Mar 31, 2026 | −$0.39 | −$0.35 | Miss −11.4% | — |
| — | Quarter ended Dec 31, 2025 | −$0.58 | −$0.32 | Miss −81.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
GLSI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Oct 26, 2026 | DEFA14A | Additional proxy material |
| Oct 26, 2026 | DEF 14A | Proxy statement (pay, board, votes) · period ended Oct 26, 2026 |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
GLSI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-0.42 | $-0.35 | −$0.07 | $0 | 2 |
| Next quarter (ends Mar 2027) | $-0.43 | $-0.30 | −$0.13 | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-1.48 | $-1.39 | −$0.09 | $0 | 2 |
| Next fiscal year (ends Dec 2027) | $-1.80 | $-1.17 | −$0.63 | $0 | 2 |
Key Statistics (as of November 18, 2026 at 17:14 UTC)
| Price | USD 20.08 |
|---|---|
| Change | ▲ 7.35% (up) |
| Previous Close | USD 18.7 |
| Open | USD 18.6 |
| Day Range | USD 18.24 – 21.22 |
| 52-Week Range | USD 7.78 – 34.1 |
| Volume | 420,435 shares |
| Market Cap | $294.67M |
| Exchange | NCM |
Technical Analysis (GLSI)
Nexqual's technical model rates GLSI "BUY" based on 5 bullish and 2 bearish signals across 129 daily candles, as of November 18, 2026 at 17:14 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.1 (neutral) |
| vs SMA50 | Above (USD 16.68) |
| MACD | 0.16 (positive) |
Analyst Ratings (GLSI)
Wall Street analysts rate GLSI "Buy" based on 2 analysts, with a mean price target of USD 57.5 (range USD 45–70), per Nexqual as of November 18, 2026 at 17:14 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 57.5 |
| High Target | USD 70 |
| Low Target | USD 45 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (GLSI)
| Next Earnings Date | 2026-11-16 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.4 vs est -0.34 ▼ miss |
| 2026-06-30 | USD -0.27 vs est -0.33 ▲ beat |
| 2026-03-31 | USD -0.39 vs est -0.35 ▼ miss |
| 2025-12-31 | USD -0.58 vs est -0.32 ▼ miss |
Source: Nexqual, November 18, 2026 at 17:14 UTC.
Financials & Fundamentals (GLSI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -11218.13% |
| Current Ratio | 0.77 |
| Total Cash | $5.90M |
| Total Debt | $0 |
Source: Nexqual, November 18, 2026 at 17:14 UTC.
Financial Health Score (GLSI)
Nexqual rates Greenwich LifeSciences, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 17:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -416.6% (last 4 quarters, SEC) |
Ownership (GLSI)
| Insider Ownership | +47.91% |
|---|---|
| Institutional Ownership | +12.45% |
| Shares Outstanding | 14.68M |
| Float | 7.65M |
| Short % of Float | +20.64% |
Source: Nexqual, November 18, 2026 at 17:14 UTC.
Leadership (GLSI)
Greenwich LifeSciences, Inc. is led by Snehal S. Patel, CEO, CFO & Director, per Nexqual as of November 18, 2026 at 17:14 UTC.
| CEO, CFO & Director | Snehal S. Patel |
|---|---|
| Founder & Independent Director | Eric Rothe |
| Chief Medical Officer & Director | Frank Joseph Daugherty |
| Vice President Clinical & Regulatory Affairs | Jaye L. Thompson |
Major Backers & Investors (GLSI)
Notable institutional backers of Greenwich LifeSciences, Inc. include Fidelity, Goldman Sachs, STRS Ohio, according to Nexqual as of November 18, 2026 at 17:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.74% |
| Goldman Sachs | 0.39% |
| STRS Ohio | 0.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.49% |
| Vanguard Group | 2.96% |
| Geode Capital | 1.28% |
| State Street | 1.09% |
| Northern Trust | 0.56% |
| BNY Mellon | 0.33% |
Source: Nexqual, November 18, 2026 at 17:14 UTC.
From Greenwich LifeSciences, Inc.'s Latest SEC 10-K Filing (filed 2026-06-01)
Key Strengths & Strategy (as disclosed to the SEC)
- HJF managed the GP2 Phase IIb clinical which was led by MD Anderson Cancer Center, oversaw all regulatory filings with the FDA for all 4 GP2 clinical trials (including the 3 Phase I and the Phase IIb clinical trials), and possesses all patient and manufacturing data from such trials.
- We also rely on trade secrets, know-how, and continuing technological innovation to develop and maintain our proprietary position. term of individual patents depends upon the legal term of the patents in countries in which they are obtained.
Partnerships
- HJF may terminate the license if we do not make required payments, if we default in our performance obligations, if we do not sufficiently develop and advance GP2 towards commercialization, and for various other reasons. connection with the exclusive license agreement with HJF, we were the financial and corporate sponsors of the GP2 Phase IIb clinical trial.
- Patent and Trademark Office in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. to our exclusive license agreement with HJF, we were granted exclusive worldwide rights to several U.S. and foreign patents and patent applications covering methods of using GP2.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 96.52 | ▼ 0.29% |
| BLTE | Belite Bio, Inc | USD 158.13 | ▲ 0.26% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.47 | ▲ 0.16% |
| IBRX | ImmunityBio, Inc. | USD 6.65 | ▲ 6.23% |
| IMVT | Immunovant, Inc. | USD 33.47 | ▲ 0.78% |
| CGON | CG Oncology, Inc. | USD 81.42 | ▲ 3.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 17:14 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt